FDA approves iPad-based blood loss monitor

The FDA gave de novo approval to Gauss Surgical's Triton Fluid Management System blood loss monitor. The approval is significant because the device uses an iPad camera and cloud analytics. The company intended to file a 510(k) but instead spent 15 months going through the de novo approval process because the FDA could not find a substantially equivalent device. Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.